Abstract
MicroRNAs (miRNAs) are a class of small (18~25 nucleotides long) non-coding RNAs that regulate gene expression on the post-transcriptional level. During the last decade, the field of miRNA research has been exponentially expanding, revealing the widespread role of these molecules in numerous biological processes. Aberrant miRNA expression has been documented in multiple haematologic malignancies, including B cell lymphomas. There is compelling evidence that miRNAs can function as oncogenes or tumor suppressor genes in lymphoid malignancies. In this review, we recapitulate the current knowledge of miRNA expression in B cell malignancies and discuss the accumulating evidence for a major role of miRNA deregulation in the development of B cell-derived lymphoid tumors.
Keywords: B cells, Hodgkin lymphoma, leukemia, lymphoma, MicroRNA.
Current Molecular Medicine
Title:Role of MicroRNAs in B Cell Leukemias and Lymphomas
Volume: 14 Issue: 5
Author(s): A. Schmidt and R. Kuppers
Affiliation:
Keywords: B cells, Hodgkin lymphoma, leukemia, lymphoma, MicroRNA.
Abstract: MicroRNAs (miRNAs) are a class of small (18~25 nucleotides long) non-coding RNAs that regulate gene expression on the post-transcriptional level. During the last decade, the field of miRNA research has been exponentially expanding, revealing the widespread role of these molecules in numerous biological processes. Aberrant miRNA expression has been documented in multiple haematologic malignancies, including B cell lymphomas. There is compelling evidence that miRNAs can function as oncogenes or tumor suppressor genes in lymphoid malignancies. In this review, we recapitulate the current knowledge of miRNA expression in B cell malignancies and discuss the accumulating evidence for a major role of miRNA deregulation in the development of B cell-derived lymphoid tumors.
Export Options
About this article
Cite this article as:
Schmidt A. and Kuppers R., Role of MicroRNAs in B Cell Leukemias and Lymphomas, Current Molecular Medicine 2014; 14 (5) . https://dx.doi.org/10.2174/1566524014666140603095414
DOI https://dx.doi.org/10.2174/1566524014666140603095414 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review
Current Drug Metabolism Nicotinamide Adenine Dinucleotide Based Therapeutics
Current Medicinal Chemistry Solubility Enhancement and Delivery Systems of Curcumin a Herbal Medicine: A Review
Current Drug Delivery Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer
Current Cancer Drug Targets The cytotoxic effect of GW843682X on nasopharyngeal carcinoma
Anti-Cancer Agents in Medicinal Chemistry Small Molecule Antagonists of Integrin Receptors
Current Medicinal Chemistry Advances in the Use of Multifunctional Mesoporous Silica Nanoparticles and Related Nanomaterials as Carriers for the Cancer Treatment
Current Drug Metabolism Moxifloxacin Based Triple Therapy as Alternative to Standard Therapy in <i>Helicobacter Pylori</i> Eradication
Anti-Infective Agents Competitive Interaction Between Plasma Omega-3 Fatty Acids and Arachidonic Acid is Related to Down-Regulation of A Signaling Mediator
Medicinal Chemistry FDG-PET/CT Radiomics Models for The Early Prediction of Locoregional Recurrence in Head and Neck Cancer
Current Medical Imaging Leptin, Ciliary Neurotrophic Factor, Leukemia Inhibitory Factor and Interleukin- 6: Class-I Cytokines Involved in the Neuroendocrine Regulation of the Reproductive Function
Current Protein & Peptide Science Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Transport of Nucleoside Analogs Across the Plasma Membrane: A Clue to Understanding Drug-Induced Cytotoxicity
Current Drug Metabolism The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies
Current Pharmaceutical Design The Quest for a Tumor Suppressor Gene Phenotype
Current Molecular Medicine Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Anti-diabetic Drug Metformin: Challenges and Perspectives for Cancer Therapy
Current Cancer Drug Targets Heavy Metals and Epigenetic Alterations in Brain Tumors
Current Genomics MicroRNA Pathways: An Emerging Role in Identification of Therapeutic Strategies
Current Gene Therapy A Mechanistic Overview on Male Infertility and Germ Cell Cancers
Current Pharmaceutical Design